🕒 Last update: loading…19/11/2026

Stock Ekso Bionics Holdings, Inc. EKSO

Ekso Bionics Holdings, Inc. — Investlytic score 0/5 on the five criteria.

-
-
0/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 0/5 criteria met. Data as of 01/11/2026.

  • ❌ Price trend failed
  • ⚠️ Mixed growth
  • ❌ Debt failed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: -68.44%

Price change 2019 → 2020: 4.43%

Price change 2020 → 2021: -56.77%

Price change 2021 → 2022: -55.09%

Price change 2022 → 2023: 110.08%

Price change 2023 → 2024: -75.60%

Price change 2024 → 2025: -5.57%

Price change 2025 → 2026: 134.14%

Price change 2026 (year to date): 158.04%

Financial growth

Revenue CAGR (8 years): 1.75%

Earnings CAGR (8 years): N/A

Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.

Debt

Debt-to-equity ratio: 0.51

Debt/equity > 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -3.11

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 31.72% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…
03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Dividends and earnings

Ekso Bionics Holdings, Inc.: dividend history, last distributions, stock splits and earnings releases.

No known dividend for this company.

Earnings releases

DatePublished EPSExpected EPSSurprise
28/04/2026-2.04-0.03n/a
23/02/2026-1.56-0.08n/a
28/10/2025-0.54-0.99n/a
28/07/2025-1.24-1.20n/a
05/05/2025-1.80-1.65n/a
03/03/2025-2.10-0.07n/a

Stock splits

DateOperation
02/06/2025reverse split: 1 share for 15
25/03/2020reverse split: 1 share for 15
05/05/2016reverse split: 1 share for 7

Factual data: ex-dividend history and earnings calendar, as of 18/11/2026. A past dividend does not guarantee the next one.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 17/01/2014
ISIN code
US2826444000
Workforce
61
full-time employees
Chief executive
Scott G. Davis

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Ekso Bionics Holdings, Inc.

Is Ekso Bionics Holdings, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US2826444000).

How many employees does Ekso Bionics Holdings, Inc. have?

61 full-time employees according to the latest published profile.

Who runs Ekso Bionics Holdings, Inc.?

Scott G. Davis is the company's chief executive.